MedTrace Logo

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

NCT05972720 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2025-05-15

No results posted yet for this study

Summary

This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Conditions

  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Interventions

DRUG

Fludarabine (Conditional therapy)

Lymphodepletion chemotherapy

DRUG

Cyclophosphamide Monohydrate (Conditional therapy)

Lymphodepletion chemotherapy

DRUG

firi-cel (Experimental drug)

Investigational agent

Sponsors & Collaborators

  • CARGO Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2025-04-04
Completion
2025-04-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05972720 on ClinicalTrials.gov